New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareNAD+ vs Semaglutide

NAD+ vs Semaglutide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
NAD+
GLP-1 / Weight Loss Agonists
Semaglutide
Summary
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells that declines dramatically with age. It is critical for energy metabolism, DNA repair, and sirtuin activation. IV and subcutaneous NAD+ supplementation is used in anti-aging protocols and addiction recovery programs.
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
Half-Life
Varies by route; IV provides direct cellular delivery
~7 days
Admin Route
IV, SubQ, Oral
SubQ, Oral
Research
Typical Dose
500–1000 mg
0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
Frequency
Daily for 4–10 days (loading), then monthly maintenance
Once weekly, subcutaneous
Key Benefits
  • Restored cellular energy production (ATP)
  • Sirtuin activation for longevity and metabolic regulation
  • Enhanced DNA repair capacity
  • Improved mitochondrial function and biogenesis
  • Cognitive clarity and mental energy
  • Reduced inflammation
  • Addiction withdrawal support (opioids, alcohol, benzodiazepines)
  • Improved sleep quality
  • Enhanced athletic endurance
  • Average 15–20% body weight reduction in clinical trials (STEP trials)
  • Significant reduction in appetite and food cravings
  • Improvement in blood sugar control and insulin sensitivity
  • Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
  • May reduce risk of kidney disease
  • Improves metabolic markers (cholesterol, blood pressure)
  • FDA-approved — extensively studied with robust safety data
  • Weekly dosing convenience
Side Effects
  • Flushing and warmth during IV infusion
  • Nausea during rapid IV administration
  • Chest tightness (from rapid infusion — slow the rate)
  • Injection site irritation (subcutaneous)
  • +1 more
  • Nausea (most common, especially during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal discomfort
  • +4 more
Stacks With